Nattokinase is a silent supplement. No acute felt effect.

• Onset: No felt effect at any timepoint. Plasma fibrinolytic activity peaks 2-8 hr post-dose; D-dimer rises but produces no perceptible sensation.
• Peak / plateau: After 4-8 weeks of daily 2000 FU/day, BP improvements (if any) are detectable on a home cuff. Lab markers (D-dimer, fibrinogen, lipid panel) move at 6-12 weeks.
• Taper: No withdrawal. Effects fade gradually over 1-2 weeks of discontinuation as endogenous fibrinolytic balance returns to baseline.
• What it does NOT feel like: Not a stimulant, not a mood lifter, not an analgesic, not an energy enhancer. Don't expect anything subjective. If a user reports acute effects, suspect placebo or the natto-specific MK-7 vitamin K2 content (relevant for whole-natto consumption, not isolated nattokinase capsules).

• Tolerance buildup: None reported. Mechanism is enzymatic / direct fibrin cleavage + endogenous-pathway modulation, not receptor-mediated. No tolerance reported in trials up to 6 months at 6000 FU/day.
• Recommended cycle: None. Daily continuous use is the standard protocol. No washout needed.
• Reset protocol: Not applicable.
• Long-term safety: Data exists out to 6 months at 6000 FU/day (Ren 2017) without major signals. Multi-year clinical-trial data is limited. Multi-decade dietary use of natto in Japan (~50 g/day in some populations) shows no population-level safety signal — though dietary natto's MK-7 vitamin K2 content has its own benefits (bone, vascular calcification) layered on top.

Synergistic with

• Nothing genuinely synergistic in the cardiovascular-prevention space — most stackable items (fish oil, garlic, hawthorn, CoQ10) overlap mechanistically without strong additive evidence. Don't stack for synergy; stack for breadth-of-coverage.
• Vitamin K2 (MK-7) — nattokinase is naturally produced by the same fermentation that produces MK-7 (whole natto contains both). Isolated nattokinase capsules typically don't contain MK-7. Important framing: taking nattokinase + separate K2 (MK-7) is nutritionally similar to eating whole natto, but K2 itself is an anticoagulant antagonist — K2 is required for synthesis of clotting factors II, VII, IX, X. So K2 + nattokinase is not additive bleeding risk; rather, K2 partially mitigates the bleeding amplification. For users on warfarin, however, this becomes more complex — K2 antagonizes warfarin. Coordinate carefully with prescriber.
• CoQ10 — different mechanism (mitochondrial); reasonable cardiovascular co-administration with no interaction concern.
• Magnesium glycinate (in user's V4 stack) — different mechanism (vasodilation, BP); modest BP-additive effect with nattokinase. Safe co-administration.
• L-arginine / L-citrulline — NO-pathway support; modest vascular synergy. No safety concern.
• Hawthorn extract — traditional CV botanical; mild synergy, no documented interaction.

Avoid stacking with

• Warfarin / DOACs / heparin — HARD CONTRAINDICATION. Bleeding amplification documented in case reports.
• Aspirin (chronic daily) — HIGH-CAUTION. Case-reported amplification of bleeding events. If aspirin 81 mg cardioprotective use is prescribed, defer nattokinase.
• Clopidogrel / ticagrelor / prasugrel — HIGH-CAUTION. Antiplatelet + fibrinolytic combination → bleeding-amplification documented.
• High-dose fish oil (>3 g EPA+DHA/day) — mild antiplatelet effect of EPA + nattokinase fibrinolytic = mild additive bleeding risk. Manageable at typical 1-2 g doses. Relevant to the user's V4 fish oil stack — Carlson DHA Gems at 1 g/day is unlikely to materially amplify; still, if nattokinase is ever added, monitor for bruising.
• Garlic supplements at high dose (>1 g aged garlic extract / >4 g raw garlic equivalent) — mild antiplatelet; additive.
• Ginkgo biloba, ginger high-dose, turmeric high-dose (>1500 mg Meriva equivalent) — all have mild antiplatelet effects; additive bleeding theoretical, case reports rare.
• Vitamin E high-dose (>400 IU/day) — antiplatelet at high dose; additive risk.
• NSAIDs (chronic) — GI bleeding risk amplified; relevant for users who self-medicate post-training inflammation.

Neutral / safe co-administration

• All canonical V4/V5 stack items not listed above: ALCAR, citicoline, alpha-GPC, magnesium threonate, phosphatidylserine, theanine, taurine, glycine, tryptophan, melatonin, D3, beta-alanine, vitamin C (mild synergy via endothelial NO).
• Modafinil — no interaction.
• BPC-157, TB-500, peptides — no documented interaction; theoretical concern about combined healing-modulation but no clinical signal.
• Caffeine — no interaction.

Nattokinase has direct pharmacodynamic interactions with all anticoagulants and antiplatelets via additive fibrinolytic / antithrombotic effects, not via CYP450 modulation:

• Warfarin: Additive bleeding risk; INR can rise unpredictably. Case reports of INR climbing from therapeutic 2-3 to 4+ after adding nattokinase. Do not combine without explicit prescriber coordination + frequent INR monitoring.
• DOACs (apixaban, rivaroxaban, dabigatran, edoxaban): No structured PK study; clinical reports suggest additive bleeding amplification. Effectively contraindicated.
• Heparin / LMWH (enoxaparin): Hospital / post-op setting only; nattokinase irrelevant in those contexts but should not be co-administered.
• Aspirin (low-dose, 81 mg): Mild additive bleeding risk; case reports of cerebral hemorrhage in combination. Avoid.
• Aspirin (high-dose, ≥325 mg) or chronic NSAIDs: Additive antiplatelet + GI mucosal risk.
• Clopidogrel, ticagrelor, prasugrel, dipyridamole: Additive antiplatelet — avoid.
• SSRIs / SNRIs: Mild antiplatelet effect from SSRIs; additive with nattokinase. Magnitude probably small; flag for users on high-dose SSRI + frequent training trauma.
• Fish oil (EPA/DHA), garlic, ginkgo, turmeric, ginger, vitamin E, ginseng: All mild antiplatelet at high doses; additive concern.
• CYP450 system: No meaningful CYP induction or inhibition reported. No relevant statin, antidepressant, or hormone interactions via that route.
• Vitamin K (K1 phylloquinone, K2 menaquinones): K is the cofactor for clotting-factor carboxylation. K supplementation partially counteracts nattokinase's antithrombotic effect (and warfarin's effect). For the user not on warfarin, this is mostly a non-issue and even potentially protective; for warfarin patients, K2 in natto / nattokinase is a major coordination problem.

For the user: not currently on any of the watch-list drugs. No drug interactions of concern in V4/V5 stack — but see fish oil note above (mild additive concern at higher fish oil doses).

Limited published pharmacogenomic data on nattokinase specifically. Several inferences from coagulation-cascade and fibrinolytic-system polymorphisms:

• F5 Leiden mutation (Factor V Leiden): Hereditary thrombophilia (~5% European-descent prevalence) → activated protein C resistance → elevated VTE risk. Carriers might benefit more from nattokinase's fibrinolytic effect, but this is theoretical — no RCT has stratified.
• Prothrombin G20210A: Similar logic — thrombophilic genotype could plausibly benefit. No data.
• PAI-1 4G/5G polymorphism: 4G/4G genotype has higher PAI-1 levels and elevated CV risk. Nattokinase lowers PAI-1 → theoretically larger benefit in 4G/4G carriers. No data.
• MTHFR C677T: Affects homocysteine, not fibrinolysis directly; no nattokinase interaction.
• VKORC1 / CYP2C9 (warfarin pharmacogenomics): Irrelevant unless on warfarin.
• APOE4: Cardiovascular risk modifier; if APOE4 + dyslipidemia + family history, the cardiovascular-prevention case strengthens marginally. No direct nattokinase pharmacogenomic interaction.
• HLA / immunogenicity: Anti-nattokinase antibodies appear in some chronic users (Suzuki 2003); HLA polymorphisms could plausibly modulate this, but no published data.

When 23andMe results land for the user (~June 2026), the nattokinase-relevant flags would be:

1. F5 Leiden / prothrombin G20210A — would shift the prevention case from "speculative" to "moderate prevention rationale."
2. PAI-1 4G/4G — same direction.
3. APOE4 + dyslipidemia developing — would marginally strengthen.

None of these would push to CONFIRMED-IN-USE for a 20yo athlete with no current thromboembolic event; they would shift the watch-list threshold for adding it later in life.

Recommendation for the user, if/when nattokinase is ever indicated: Doctor's Best Nattokinase 2000 FU from iHerb fits the existing channel and uses NSK-SD (clinically validated). Take on empty stomach 30+ min before breakfast. Budget tier (~$3/mo at 1 cap/day) — cost is negligible if needed.

Current recommendation: do NOT add to V4/V5 stack. No current cardiovascular indication. Bleeding-amplification concern with V4 fish oil + occasional NSAIDs + daily MMA impact dominates the modest prevention upside. Reassess at 6-month bloodwork if BP, fibrinogen, D-dimer, or lipid panel develops actionable signal.

• Baseline (before starting / on June 2026 panel):

  • BP — systolic / diastolic, ideally home cuff measurements averaged over 1 week. Most important efficacy marker.
  • Lipid panel (TC, LDL-C, HDL-C, TG, ApoB if available) — secondary efficacy + risk-stratification.
  • Fibrinogen — direct mechanistic target; expect ↓ at 8-12 weeks if responsive.
  • D-dimer — if elevated at baseline (chronic inflammation, post-COVID, long-haul travel pattern), nattokinase rationale strengthens.
  • CBC + platelet count — baseline for bleeding-risk surveillance.
  • PT / INR / PTT — if any concern about coagulation function or before adding any antithrombotic.
  • hsCRP, IL-6 (specialty) — secondary inflammation markers.
  • Homocysteine — independent CV risk factor; not directly modulated by nattokinase but worth pairing.
  • Subjective: bruising frequency / severity (1-10 scale), nosebleed frequency, gum bleeding.

• During use (4-week, 12-week, 6-month, annual cadence):

  • BP — weekly home cuff for first month, then monthly.
  • Fibrinogen, D-dimer — recheck at 12 weeks.
  • Lipid panel — recheck at 12 weeks if added for lipid indication.
  • CBC, PT/PTT — annually.
  • Subjective bleeding signs — ongoing.

• Post-cycle: N/A (no cycling).

For the user specifically: piggyback on the June 2026 baseline panel. Look for BP trends, fibrinogen, D-dimer, lipid panel. If all values are unremarkable for a 20yo athlete, no nattokinase added. If BP creeps above 130 systolic, fibrinogen >350 mg/dL, or D-dimer is elevated without obvious cause, revisit at the 12-month bloodwork point.